Our Programs

Our Focus

We are committed to advancing novel therapies that aim to address the unmet needs of autoimmune and inflammatory diseases. We are currently advancing voclosporin for the treatment of lupus nephritis (LN) and focal segmental glomerulosclerosis (FSGS). Additionally, we are developing voclosporin ophthalmic solution (VOS) for the treatment of dry eye syndrome (DES).

pipeline mobile